Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
344 GBX | -1.71% | +11.69% | +21.55% |
14/05 | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
14/05 | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.55% | 375.03Cr | |
+31.06% | 68TCr | |
+30.35% | 59TCr | |
-3.42% | 36TCr | |
+18.02% | 33TCr | |
+4.27% | 28TCr | |
+15.53% | 24TCr | |
+10.16% | 21TCr | |
-8.14% | 20TCr | |
+8.12% | 17TCr |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : HUTCHMED Limited, Q2 2023 Earnings Call, Jul 31, 2023